Wire
Moderna Says European Commission Grants Marketing Authorization for mCombriax Vaccine for Influenza, COVID-19
Moderna (MRNA) said Tuesday the European Commission has granted marketing authorization for its mCombriax vaccine for the prevention of influenza and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older.The marketing authorization is valid in all 27 European Union member states, as well as Iceland, Liechtenstein and Norway, Moderna said.The Commission's authorization is based on the results from the phase 3 clinical study evaluating the safety, reactogenicity, and immunogenicity of mCombriax in two independent age groups of about 4,000 adults each, Moderna said.Price: $54.02, Change: $-0.57, Percent Change: -1.04%
$MRNA